Serena Williams' weight loss was aided GLP-1 medication for weight loss, losing 31 pounds. The tennis legend speaks on ...

Eli Lilly's orforglipron could have a few advantages over a pill from Novo Nordisk, including a lack of dietary restrictions ...

The company raised its full-year revenue guidance from a range of $58 billion to $61 billion to a range of $60 billion to $62 ...

Can Novo Nordisk and Eli Lilly regain their former stock market glory? A lot is riding on next year's pills ...

The people of Northern Gaza are starving. That’s according to an official declaration by a United Nations-backed group of ...

In the past couple years, demand has gone wild for drugs like Ozempic – and its cousins, Zepbound, Wegovy, and Mounjaro. For ...

Through innovation, cost discipline, legal action, and competitive pricing, Novo Nordisk has reasserted its leadership in the GLP-1 market. With a robust pipeline and global expansion, NVO is poised ...

A Comeback Fueled by Resilience Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) has been a trailblazer in the GLP-1 drug ...

Tennis star Serena Williams' candor about her GLP-1 use may help dispel the pesky health inaccuracy that weight loss is a ...

Serena Williams has revealed she lost 31 pounds on the GLP-1 Zepbound: "I just couldn't get my weight to where I needed to be at a healthy place." ...

People with type 2 diabetes treated with GLP-1 receptor agonists may face a slightly higher risk for eye complications ...

There’s still much more to come from the White House on tariffs, but the European Union has now reached a trade agreement ...